B-condition	0	4	Bone
I-condition	5	14	fractures
O	15	20	among
O	21	35	postmenopausal
O	36	44	patients
O	45	49	with
O	50	59	endocrine
O	59	60	-
O	60	70	responsive
O	71	76	early
O	77	83	breast
O	84	90	cancer
O	91	98	treated
O	99	103	with
O	104	105	5
O	106	111	years
O	112	114	of
B-intervention	115	124	letrozole
O	125	127	or
B-control	128	137	tamoxifen
O	138	140	in
O	141	144	the
O	145	148	BIG
O	149	150	1
O	150	151	-
O	151	153	98
O	154	159	trial
O	159	160	.

O	161	163	To
O	164	171	compare
O	172	175	the
O	176	185	incidence
O	186	189	and
O	190	196	timing
O	197	199	of
O	200	204	bone
O	205	214	fractures
O	215	217	in
B-eligibility	218	232	postmenopausal
I-eligibility	233	238	women
I-eligibility	239	246	treated
I-eligibility	247	251	with
I-eligibility	252	253	5
I-eligibility	254	259	years
I-eligibility	260	262	of
I-eligibility	263	271	adjuvant
I-eligibility	272	281	tamoxifen
I-eligibility	282	284	or
I-eligibility	285	294	letrozole
I-eligibility	295	298	for
I-eligibility	299	308	endocrine
I-eligibility	308	309	-
I-eligibility	309	319	responsive
I-eligibility	320	325	early
I-eligibility	326	332	breast
I-eligibility	333	339	cancer
O	340	342	in
O	343	346	the
O	347	353	Breast
O	354	367	International
O	368	373	Group
O	374	375	(
O	375	378	BIG
O	378	379	)
O	380	381	1
O	381	382	-
O	382	384	98
O	385	390	trial
O	390	391	.

O	392	394	We
O	395	404	evaluated
B-total-participants	405	409	4895
O	410	418	patients
O	419	428	allocated
O	429	431	to
O	432	433	5
O	434	439	years
O	440	442	of
O	443	452	letrozole
O	453	455	or
O	456	465	tamoxifen
O	466	468	in
O	469	472	the
O	473	476	BIG
O	477	478	1
O	478	479	-
O	479	481	98
O	482	487	trial
O	488	491	who
O	492	500	received
O	501	503	at
O	504	509	least
O	510	514	some
O	515	520	study
O	521	531	medication
O	532	533	(
O	533	539	median
O	540	546	follow
O	546	547	-
O	547	549	up
O	550	552	60
O	552	553	.
O	553	554	3
O	555	561	months
O	561	562	)
O	562	563	.

O	564	568	Bone
O	569	577	fracture
O	578	589	information
O	590	591	(
O	591	596	grade
O	596	597	,
O	598	603	cause
O	603	604	,
O	605	609	site
O	609	610	)
O	611	614	was
O	615	624	collected
O	625	630	every
O	631	632	6
O	633	639	months
O	640	646	during
O	647	652	trial
O	653	662	treatment
O	662	663	.

O	664	667	The
B-outcome	668	677	incidence
I-outcome	678	680	of
I-outcome	681	685	bone
I-outcome	686	695	fractures
O	696	699	was
O	700	706	higher
O	707	712	among
O	713	721	patients
O	722	729	treated
O	730	734	with
O	735	744	letrozole
O	745	746	[
B-iv-bin-abs	746	749	228
O	750	752	of
B-intervention-participants	753	757	2448
O	758	763	women
O	764	765	(
B-iv-bin-percent	765	766	9
I-iv-bin-percent	766	767	.
I-iv-bin-percent	767	768	3
I-iv-bin-percent	768	769	%
O	769	770	)
O	770	771	]
O	772	778	versus
O	779	788	tamoxifen
O	789	790	[
B-cv-bin-abs	790	793	160
O	794	796	of
B-control-participants	797	801	2447
O	802	807	women
O	808	809	(
B-cv-bin-percent	809	810	6
I-cv-bin-percent	810	811	.
I-cv-bin-percent	811	812	5
I-cv-bin-percent	812	813	%
O	813	814	)
O	814	815	]
O	815	816	.

O	817	820	The
O	821	826	wrist
O	827	830	was
O	831	834	the
O	835	839	most
O	840	846	common
O	847	851	site
O	852	854	of
B-outcome	855	863	fracture
O	864	866	in
O	867	871	both
O	872	881	treatment
O	882	888	groups
O	888	889	.

O	890	903	Statistically
O	904	915	significant
O	916	920	risk
O	921	928	factors
O	929	932	for
O	933	937	bone
O	938	947	fractures
O	948	954	during
O	955	964	treatment
O	965	973	included
O	974	977	age
O	977	978	,
O	979	986	smoking
O	987	994	history
O	994	995	,
O	996	1008	osteoporosis
O	1009	1011	at
O	1012	1020	baseline
O	1020	1021	,
O	1022	1030	previous
O	1031	1035	bone
O	1036	1044	fracture
O	1044	1045	,
O	1046	1049	and
O	1050	1058	previous
O	1059	1066	hormone
O	1067	1078	replacement
O	1079	1086	therapy
O	1086	1087	.

O	1088	1098	Consistent
O	1099	1103	with
O	1104	1109	other
O	1110	1116	trials
O	1117	1126	comparing
O	1127	1136	aromatase
O	1137	1147	inhibitors
O	1148	1150	to
O	1151	1160	tamoxifen
O	1160	1161	,
O	1162	1171	letrozole
O	1172	1175	was
O	1176	1186	associated
O	1187	1191	with
O	1192	1194	an
O	1195	1203	increase
O	1204	1206	in
O	1207	1211	bone
O	1212	1221	fractures
O	1221	1222	.

O	1223	1231	Benefits
O	1232	1234	of
O	1235	1243	superior
O	1244	1251	disease
O	1252	1259	control
O	1260	1270	associated
O	1271	1275	with
O	1276	1285	letrozole
O	1286	1289	and
O	1290	1295	lower
O	1296	1305	incidence
O	1306	1308	of
O	1309	1317	fracture
O	1318	1322	with
O	1323	1332	tamoxifen
O	1333	1339	should
O	1340	1342	be
O	1343	1353	considered
O	1354	1358	with
O	1359	1362	the
O	1363	1367	risk
O	1368	1375	profile
O	1376	1379	for
O	1380	1390	individual
O	1391	1399	patients
O	1399	1400	.
